Open AccessReduction of bone mineral density by gonadotropin‐releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration
Author(s) -
Taga Michiyoshi,
Minaguchi Hiroshi
Publication year - 1996
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016349609033310
Subject(s) - medicine , bone mineral , bone density , endocrinology , bone remodeling , endometriosis , urology , osteoporosis
Study Objective. To determine the reversibilty of bone mineral density after the cessation of GnRH agonist treatment for endometriosis. Design. Longitudinal trial with 6‐month treatment period and 6‐month follow‐up. Patients. 28 Japanese premenopausal women with endometriosis. Interventions. Daily dose of 400 μg nafarelin was administered for 6 months. Measurement and main results. The spine bone mineral density was measured by dual energy X‐ray absorptiometry, and blood and urinary bone metabolic parameters were analyzed. The decrease of lumbar bone mineral density, which took place during treatment, continued during the first 3 months after the cessation of treatment and did not return to the initial baseline level even at 6 months after the withdrawal of treatment. The biochemical parameters, which showed a state of enhanced bone turnover during nafarelin treatment, almost returned to the pretreatment level 6 months after the termination of treatment. Conclusion. These results indicate that relatively long period of bone metabolic change might be required to alter the actual bone mineral density after GnRH analog administration.